Neovasc touts Tiara TMVR success rate in study

A small study of the Neovasc (NSDQ:NVCN) Tiara transcatheter mitral valve replacement (TMVR) in high-risk patients revealed a 100% procedural success rate and immediate elimination of mitral regurgitation.

Published in Circulation: Cardiovascular Interventions, the study also showed no death, myocardial infarction, stroke, major bleeding, or access site complications at 30 days. The twelve patients in the study had had a previous aortic valve replacement. Such patients have been excluded from most TMVR trials because of the potential risks of left ventricular outflow tract obstruction or interaction between the TMVR anchoring mechanism and the aortic prosthesis, according to the study.

Get the full story on our sister site, Mass Device.

See the next generation of leaders at DeviceTalks West On December 11-12, DeviceTalks West is taking over Orange County's medtech industry with one of the most anticipated conferences of the winter, bringing you the best and brightest minds in the industry. Keynote Speakers Dr. Robert Greenberg, Executive Chairman, Alfred E. Mann Foundation Gary Guthart, President and Chief Executive Officer, Intuitive Surgical Reggie Groves, CEO, REVA Medical REGISTER NOW Use code KEYNOTE to save an additional 10%.